Preclinical studies showed promising anti-leukemia activity of dasatinib in ABL class Ph-like B-ALL cells in vitro and in patient derived xenograft (PDX) models (3, 17, 20). This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.